ClinicalTrials.gg
RecruitingNCT06164808CATCHUpdated Jun 9, 2026

Cardiac Arrhythmia Telemetry; Conventional vs HeartWatch

An interventional study of HeartWatch in Cardiac Arrhythmia, Diagnostic/Monitoring Devices Related to Adverse Incidents and Atrial Fibrillation (AF), sponsored by HelpWear Inc.. Recruiting at 1 site in Canada. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.

Primary conditionAtrial FibrillationRegistry: Arrhythmias, CardiacReclassifiedWhy we changed it
Registry
Arrhythmias, Cardiac — the first condition term the registry derived for this study.
ClinicalTrials.gg
Atrial Fibrillation
Why
  1. The study's listed conditions name Atrial Fibrillation, a narrower term within Arrhythmias, Cardiac.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by HelpWear Inc. · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 318 studies in Atrial Fibrillation with a site in Canada — 50 open to participants now, 73 under way, 8 of them phase 3. Atrial Fibrillation · Canada.

Planned enrollment
124th of 261
300 · median 282
Started
2024
with 19 others
No phase
135 of 318
28 open now
Primary completion
2026-12
later than 21 of 72 live
Registered
284th of 318
by date

Among the 318 studies in Atrial Fibrillation with a site in Canada, this one is the 124th largest by planned enrollment of the 261 interventional ones that give a count, is one of 20 that started in 2024, is one of 135 with no phase, reaches primary completion later than 21 of the 72 other live ones, and was the 284th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

50 of the 318 studies in Atrial Fibrillation with a site in Canada are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 318 studies in Atrial Fibrillation with a site in Canada, or all of them as a file.
02

Study summary

Heart rhythm disorders are common and significantly impact the lives of those affected and their families. The main problems can be categorized as: a) atrial fibrillation or AF and atrial flutter, b) supra-ventricular tachycardia or SVT, c) excessively slow heart beats (i.e., bradycardia or pauses) and d) ventricular arrhythmias. These problems can be difficult to detect with currently available monitoring options as they are all worn for shorter terms or are an invasive implantable option. The HeartWatch is a longer term monitoring system that is worn on the upper arm, allows users to create a tag and pairs with an app on a smartphone allowing for correlation of symptoms.

Read the detailed description

Patients who are being referred to wear a holter monitor will be approached to wear a HeartWatch simultaneously. This will allow collection of signals on both devices and to compare the accuracy of signals between the Heartwatch vs Holter monitor. It will also examine the reliability of autodetect algorythms between the devices. We will also collect information to compare the amount of adverse events between the various systems and the patient preference of those systems.

03

Conditions studied

  • Cardiac Arrhythmia
  • Diagnostic/Monitoring Devices Related to Adverse Incidents
  • Atrial Fibrillation (AF)

Browse trials for

04

In context

Atrial Fibrillation Reclassified

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

This study's planned enrollment of 300 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

HelpWear Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Compared within Atrial Fibrillation, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Arrhythmias, Cardiac. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 22 years of age at time of consent
  • Clinically indicated for a Holter monitor test
  • Able to wear the HeartWatch on the left bicep for the study duration
  • Able to follow the protocol
  • No functional implantable pacemaker or defibrillator
  • Left bicep circumference >/= 22 cm and \</= 45 cm
  • Provision of written-

Exclusion criteria

Exclusion Criteria:

  • Known allergy to any component of the Holter monitor
  • Known allergy to any component of the HeartWatch
  • Inability to wear the HeartWatch on the left arm for the study period due to pre-existing medical condition (3.g., functional AV fistula in left arm, prior carcinoma with lymph node dissection or lymphedema, known blood clot of recurrent blood clots in the left arm, chronic neuropathic pain in left arm, ...)
  • Dextrocardia
  • Implanted functional Pacemaker or Defibrillator
  • Left bicep circumference \< 22 cm
  • Left bicep circumference \< 45 cm
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Other
    Active device engagement

    All subjects will wear either the Holter monitor and the HeartWatch.

    Device: HeartWatch

Interventions

  • DeviceHeartWatch

    The HeartWatch is indicated for the extended diagnostic evaluation of patients with symptomatic and transient symptoms such as light-headedness, syncope, and palpitations, as well as patients at risk for arrhythmias, but without significant symptoms. It is an armband consisting of the main body of the device with an additional sensor located on the band. It is worn around the upper left arm to obtain heart electrical signals. The device is paired with the HelpWear application on a smartphone where the signals are stored and then will be uploaded to a secure network for analysis.

07

What researchers measure

Primary outcomes

  1. QRS signal detection

    Compare QRS detection accuracy with HeartWatch data vs. the Holter monitor lead I signal

    Time frame: For the duration of time that the patient wears the Holter monitor and the HeartWatch, 24-48 hours

Secondary outcomes

  1. ECG strip evaluation

    Compare the overall agreement of the HeartWatch vs. Holter data in providing interpretable ECG strips data for all symptomatic (patient tagged) events and all cardiologist-verified non-normal rhythms identified by cardiology technologists (Holter).

    Time frame: For the duration of time that the subject wears the holter vs the HeartWatch (24-48 hours).

  2. ECG PR interval assessment

    Assess the comparability of paired, 10-minute averaged PR intervals measured from the HeartWatch vs. the Holter lead I reference signal.

    Time frame: For the duration of time that the subject wears the holter vs the HeartWatch (24-48 hours).

  3. ECG QRS interval assessment

    Assess the comparability of paired, 10-minute averaged QRS intervals measured from the HeartWatch vs. the Holter lead I reference signal.

    Time frame: For the duration of time that the subject wears the holter vs the HeartWatch (24-48 hours).

  4. ECG interval assessment

    Assess the comparability of paired, 10-minute averaged heart rate corrected QT (QTc) intervals measured from the HeartWatch vs. the Holter lead I reference signal.

    Time frame: For the duration of time that the subject wears the holter vs the HeartWatch (24-48 hours).

Other outcomes

  1. Adverse events

    Evaluate and describe adverse events related to the use of the HeartWatch and Holter devices.

    Time frame: For the duration of time that the subject wears the holter vs the HeartWatch (24-48 hours).

  2. User preference

    Compare user preferences for the HeartWatch and Holter devices

    Time frame: For the duration of time that the subject wears the holter vs the HeartWatch (24-48 hours).

  3. ECG strip categorization

    Compare ECG strip categorizations of the HeartWatch vs. the Holter.

    Time frame: For the duration of time that the patient wears the Holter monitor and the HeartWatch, 24-48 hours.

  4. Future software validation

    To use the ECG data signals collected to validate future software

    Time frame: Data obtained during the recordings will be used for future software validation for 5 years.

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 34 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2023
First posted
Dec 11, 2023
StartActual
Feb 20, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06164808
Lead sponsor
HelpWear Inc.
Responsible party
Sponsor
First posted
Dec 11, 2023
Start date
Feb 20, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 9, 2026

Study contacts

Karen Cowan
Contact
kcowan@ucalgary.ca
4035600225
Owen Gillett
Contact
owen.gillett@helpwear.ca
647-994-4077
Russell Quinn, MD
principal investigator · University of Calgary

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion